HIV infection has infected over 33 million people worldwide. Though highly activated anti-retroviral therapy (HAART) has been effective at controlling infection leading to a better long-term outcome for patients, it has failed to eradicat the latently reservoir. There is a critical need to develop approaches that can lead to a functiona cure. The overall objectives of this application are to evaluate therapeutic vaccination approaches to enhance the immune system mediated clearance of latently infected cells.
In Specific aim 1, we will determine is therapeutic vaccine can be used to enhance B cell responses and if these responses can clear the latent virus.
In Specific aim 2, we will determine if NK cell activity can be enhanced leading to better elimination of latently infected cells. Overal these studies have the potential to lead to a functional cure and better long-term outcome.

Public Health Relevance

HIV causes immunodeficiency very rapidly by killing the cells it infects. A number of cells become latently infected and stay hidden from the immune system. Eradicating these cells is essential to obtain a functional cure. This project explores the role of vaccination in eradicating the oral reservoir during HIV infection using the non-human primate model. The studies proposed here will aid in the development of a better therapeutic approach against HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56AI125260-01
Application #
9305815
Study Section
Special Emphasis Panel (ZRG1-AARR-M (02)M)
Program Officer
Sanders, Brigitte E
Project Start
2016-07-26
Project End
2017-06-30
Budget Start
2016-07-26
Budget End
2017-06-30
Support Year
1
Fiscal Year
2016
Total Cost
$703,973
Indirect Cost
$247,608
Name
Henry M. Jackson Fdn for the Adv Mil/Med
Department
Type
DUNS #
144676566
City
Bethesda
State
MD
Country
United States
Zip Code
20817